No Data
Jiangsu Boqian New Materials Stock (605376.SH) received a warning letter from Jiangsu Securities Regulatory Bureau.
Jiangsu Boqian New Materials Stock (605376.SH) announced that the company received notice from the China Securities Regulatory Commission on January 21, 2025...
Jiangsu Boqian New Materials Stock (605376.SH): The various ultrafine Metal powder materials produced have not yet been applied in the Brain-computer Interface field.
On January 17, Glehanghui reported that Jiangsu Boqian New Materials Stock (605376.SH) stated on the investor interaction platform that Shanghai Chuang Medical Technology Co., Ltd. is an innovative enterprise engaged in the research, production, and sales of new controllable biodegradable medical magnesium Alloy materials for implantable medical instruments. Currently, it has not been involved in Brain-computer Interface related Business. As of now, the various ultra-fine Metal powder materials produced by the company have not yet been applied in the Brain-computer Interface field. The company will continue to upgrade and optimize existing products and develop and promote new products, actively expanding the application range and fields of its products, and continue to enhance the company's market competitiveness and profitability.
Jiangsu Boqian New Materials Stock (605376.SH): New Hui Investment's shareholding has decreased to 5%.
Jiangsu Boqian New Materials Stock (605376.SH) issued an announcement, stating that on January 16, 2025, it received notice from shareholders holding more than 5% of the shares...
Estimating The Intrinsic Value Of Jiangsu Boqian New Materials Stock Co., Ltd. (SHSE:605376)
Some Investors May Be Worried About Jiangsu Boqian New Materials Stock's (SHSE:605376) Returns On Capital
Jiangsu Boqian New Materials Stock (605376.SH): plans to sign an Equity Transfer Agreement.
On December 20th, Gelonghui reported that Jiangsu Boqian New Materials Stock (605376.SH) announced that the company signed an "Equity Transfer Agreement" with Mr. Ding Wenjiang, Mr. Yuan Guangyin, and Hu Chuang Medical. To seize the development opportunities of new controllable degradable medical Magnesium Alloy implant medical instruments, integrate both parties' CNI Resource Index in their respective fields, expand the company’s layout in the field of new Magnesium Alloy materials, and enhance the company's comprehensive competitiveness, the company intends to use its own or raised funds of 52.5 million yuan to acquire Mr. Ding Wenjiang's 6.4024% equity in Hu Chuang Medical, corresponding to a registered capital of 0.980172 million yuan; and to use its own or raised funds of 22.5 million.
Jiangsu Boqian New Materials Stock (SHSE:605376) Is Reinvesting At Lower Rates Of Return